With Midterms Looming, Journalists Consider Measles, Food Recalls, and Obamacare
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
FDA
1-20 of 476 results
-
-
Trump and Kennedy’s Health Industry Deals Haven’t Been Enforced and Are at Risk of Vanishing
The agreements, covering issues like drug pricing, reducing the use of synthetic food dyes, and cutting back on insurance prior authorization rules, were announced with fanfare and touted as victories. But it’s not clear whether they’ll result in lasting change.
-
How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages
Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side effects.
By Arthur Allen -
Watch: Why Abortions Are on the Rise Since ‘Roe’ Was Overturned
The way people undergo abortions has changed. This video details five things to know.
By Kate Wells and Hannah Norman -
Journalists Catch You Up on Fauci Hearing, Peptides, and Kids’ Caffeine Consumption
KFF Health News journalists made the rounds on national or local media recently to discuss topical stories. Here’s a collection of their appearances.
-
Cyclospora Boosts Fears That Worse Foodborne Outbreaks Are Ahead
The recent outbreak of a foodborne parasite sickened thousands and hospitalized hundreds across the U.S. before federal investigators identified the suspected source. Food safety experts say cuts to the public health system hobbled the response — and that the next outbreak could be much worse.
By Kate Wells and Stephanie Armour -
Lawmakers Look To Make Abortion Shield Laws Less Dependent on Who’s Governor
California’s laws still leave extradition decisions related to reproductive rights and gender-affirming care to its governor. But as states with abortion bans target California physicians who prescribe abortion pills across state lines, Democrats want to lock in protections for doctors, no matter who the next governor is.
-
A Mom Said Infant Formula Killed Her Baby. The Manufacturer Closed the File.
When makers of infant formula hear that babies got sick or died while using their products, what happens next is left largely to the manufacturers. They decide whether to inform the FDA about possible harm, which could trigger steps to protect the public.
By David Hilzenrath and Holly K. Hacker -
Reporters Talk Through FDA Sunscreen Move and Closure of Rural Dialysis Clinics
KFF Health News journalists made the rounds on national media last week to discuss topical stories. Here’s a collection of their appearances.
-
A Ban Won’t Stop Abortion Pill Access, Telehealth Providers Say
As a federal court mulls a case that could result in significant restrictions on a pill used in most abortions, providers say they have alternatives to preserve access even in states with bans in place.
By Kate Wells -
Tennessee Pharmacies Sell Potent Ivermectin, Led by Anti-Vaccine Doctor Who’s Taken ‘Bucketloads’
Four years after the Volunteer State enacted the nation’s first law allowing drugstores to sell ivermectin without patient-specific prescriptions, dozens of pharmacies dispense the drug in highly concentrated pills — many with the help of one anti-vaccine physician.
By Brett Kelman and Rachana Pradhan -
Trump Bought Tobacco Stocks and Raked In Industry Donations as FDA Eased Standards
The Trump administration has pursued an extensive pro-tobacco agenda as the president and his political movement have been buoyed by a flood of tobacco industry money, federal records show.
By Darius Tahir -
FDA’s Greenlight of Old Chemical Offers Chance To Restore Faith in Sunscreen
The FDA has approved the sunscreen chemical bemotrizinol, a UV light filter that has been available in Europe, Asia, and Australia for more than 20 years. Health advocates and skin care industry groups alike are hopeful it can restore faith in sunscreen.
-
Telehealth Booms as Demand for GLP-1s Surges and Questions Mount About Safety, Oversight
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
By Lauren Sausser and Maia Rosenfeld -
Amid Ebola, Hantavirus Outbreaks, Democrats Decry Trump’s Health Cuts
Infectious disease specialists say the viruses are unlikely to become pandemics, but some are still raising concerns about the federal health response and what it portends should a pandemic similar to or worse than covid occur.
-
What the Health? From KFF Health News
Watch: The Tug-of-War Over Taxpayer Dollars
Podcast host Julie Rovner chats with Sen. Tammy Baldwin, a top Democrat on health issues, about President Donald Trump’s stewardship of federal spending and the effectiveness of the 988 Suicide & Crisis Lifeline.
By Julie Rovner and Hannah Norman -
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
By Arthur Allen -
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
By Elisabeth Rosenthal and Arthur Allen -
Journalists Capsulize Weight Loss News and ACA Premium Pressures
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
A Headless CDC
Episode 439The Trump administration faces the challenge of naming a new director of the Centers for Disease Control and Prevention who can both satisfy the Make America Healthy Again movement and get confirmed by the Senate. Meanwhile, a new Senate bill to rescind the approval of the abortion pill mifepristone is again elevating the abortion debate, which some Republicans would prefer to stay on the back burner until after the midterms. Shefali Luthra of The 19th, Lizzy Lawrence of Stat, and Rachel Cohrs Zhang of Bloomberg News join KFF Health News’ Julie Rovner to discuss the news. Also this week, Rovner interviews Georgetown University Law Center’s Katie Keith about the state of the Affordable Care Act on its 16th anniversary.